Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Ublituximab in Multiple sclerosis relapse: NCT07225361 Clinical Landscape Report 2026
15 October 2026
NCT07225361 clinical landscape for Multiple sclerosis relapse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Afimkibart in Dermatitis, Atopic: NCT07223697 Clinical Landscape Report 2026
15 October 2026
NCT07223697 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GC-012F in Multiple Sclerosis: NCT07224373 Clinical Landscape Report 2026
15 October 2026
NCT07224373 clinical landscape for Multiple Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Remibrutinib in Multiple Sclerosis, Secondary Progressive: NCT07225504 Clinical Landscape Report 2026
15 October 2026
NCT07225504 clinical landscape for Multiple Sclerosis, Secondary Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
MEN-2501 in Platinum-Resistant Ovarian Carcinoma: NCT07226427 Clinical Landscape Report 2026
15 October 2026
NCT07226427 clinical landscape for Platinum-Resistant Ovarian Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Rinatabart Sesutecan in Platinum-Sensitive Ovarian Carcinoma: NCT07225270 Clinical Landscape Report 2026
15 October 2026
NCT07225270 clinical landscape for Platinum-Sensitive Ovarian Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Efavirenz in Primary Peritoneal High-Grade Serous Adenocarcinoma: ACTRN12625001259437 Clinical Landscape Report 2026
15 October 2026
ACTRN12625001259437 clinical landscape for Primary Peritoneal High-Grade Serous Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context…
9 min read
JNJ-95597528 in Dermatitis, Atopic: NCT07230860 Clinical Landscape Report 2026
15 October 2026
NCT07230860 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carfilzomib in Relapse multiple myeloma: NCT07227311 Clinical Landscape Report 2026
15 October 2026
NCT07227311 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cilastatin Sodium in Ovarian Cancer: NCT07229040 Clinical Landscape Report 2026
15 October 2026
NCT07229040 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Acute Myeloid Leukemia: NCT07228273 Clinical Landscape Report 2026
15 October 2026
NCT07228273 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SYS-6002 in Metastatic Carcinoma to the Uterine Cervix: NCT07230626 Clinical Landscape Report 2026
15 October 2026
NCT07230626 clinical landscape for Metastatic Carcinoma to the Uterine Cervix: endpoints, sponsor, phase, geography, readouts, asset context and development…